IBEX 35
10.902,00 -198,80 (-1,79%) Euro Stoxx 50
4.943,14 -37,95 (-0,76%) Dólar/Euro
1,0700 -0,0025 (-0,24%) Petróleo Brent
87,73 -0,67 (-0,76%) Oro
2.304,50 -53,20 (-2,26%) Bitcoin EUR
58.726,11 -631,68 (-1,06%)
Adaptive Biotechnologies Corporation (ADPT)
Adaptive Biotechnologies Corporation
1165 Eastlake Avenue East
Seattle, WA 98109
United States
206 659 0067
https://www.adaptivebiotech.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 709
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Ms. Julie Rubinstein | President & COO | 721,04k | N/A | 1972 |
| Dr. Harlan S. Robins Ph.D. | Co-Founder & Chief Scientific Officer | 711,09k | N/A | 1973 |
| Ms. Stacy L. Taylor | Senior VP, General Counsel & Corporate Secretary | N/A | N/A | 1960 |
| Ms. Mary Pat Lancelotta | Senior Vice President of MRD BioPharma | N/A | N/A | N/A |
Descripción
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Gobierno corporativo
El ISS Governance QualityScore de Adaptive Biotechnologies Corporation, a día 29 de abril de 2024, es 8. Las puntuaciones base son Auditoría: 6; Tablero: 8; Derechos de los accionistas: 8; Compensación: 8.
